The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Global

PositiveID Corporation Receives an Additional Key Patent for Fieldable Biological Detection

03-Aug-2011 | Source : | Visits : 8833
DELRAY BEACH, Fla. - PositiveID Corporation, a developer of medical technologies for diabetes management, clinical diagnostics and bio-threat detection, announced in a press release that it has been awarded an additional important international patent "Apparatus and Method of Extracting and Optically Analyzing an Analyte from a Fluid-based Sample," (WO2008/005166) by the World Intellectual Property Organization. 

The technology represented by this new patent, awarded to the Company's MicroFluidic Systems ("MFS") subsidiary, works in conjunction with the patented technology which the Company announced in mid-July. The technologies provide key steps in accurate biological sample preparation and detection with limited resources, and in the field or clinical environment. 

The handheld instrument is small enough, about the size of a syringe, that it could be carried easily by a medical provider and used with a minimal amount of training and time. This technology can allow rapid detection within minutes of a sampling allowing appropriate treatment for infected individuals immediately. The system works entirely on batteries. 

Dr. M. Allen Northrup, CEO of MFS, said, "The two new patents announced over the past couple of weeks are noteworthy for their ability to run biological sample analysis in a small, portable and cost-efficient format and provide rapid, accurate detection. We believe this technology has significant value for multiple applications of critical importance to prevent disease outbreaks and save lives." 

The unique component of the technology is a very low power optical analysis system directly coupled to the collection system to perform optical analysis on multiple collected analytes. The purification device includes a plurality of capture surfaces coated with specific capture chemistries. The specific capture can be for a nucleic acid, protein or other target analyte, and multiple options for optical detection exist.
PositiveID acquired MFS in May 2011. MFS specializes in the production of automated instruments for a wide range of applications in the detection and processing of biological samples. MFS' strong portfolio of intellectual property related to sample preparation and rapid medical testing applications are complementary to PositiveID's portfolio of virus detection and diabetes management products. 

PositiveID Corporation develops unique medical devices and biological detection systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MicroFluidic Systems, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit

Related Articles